Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 289 to 291 of 291 entries
Sorted by: Best Match Show Resources per page
Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations.

Molecular therapy : the journal of the American Society of Gene Therapy

Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, Turunen JJ, Chan HL, Schulkens IA, Vorthoren L, den Besten C, Buil L, Schmidt I, Miao J, Venselaar H, Zang J, Neuhauss SCF, Peters T, Broekman S, Pennings R, Kremer H, Platenburg G, Adamson P, de Vrieze E, van Wijk E.
PMID: 33895329
Mol Ther. 2021 Aug 04;29(8):2441-2455. doi: 10.1016/j.ymthe.2021.04.024. Epub 2021 Apr 23.

Mutations in USH2A are among the most common causes of syndromic and non-syndromic retinitis pigmentosa (RP). The two most recurrent mutations in USH2A, c.2299delG and c.2276G > T, both reside in exon 13. Skipping exon 13 from the USH2A...

Cite
Dulla K, Slijkerman R, van Diepen HC, et al. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021;29(8):2441-2455doi: 10.1016/j.ymthe.2021.04.024.
Dulla, K., Slijkerman, R., van Diepen, H. C., Albert, S., Dona, M., Beumer, W., Turunen, J. J., Chan, H. L., Schulkens, I. A., Vorthoren, L., den Besten, C., Buil, L., Schmidt, I., Miao, J., Venselaar, H., Zang, J., Neuhauss, S. C. F., Peters, T., Broekman, S., Pennings, R., Kremer, H., Platenburg, G., Adamson, P., de Vrieze, E., & van Wijk, E. (2021). Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Molecular therapy : the journal of the American Society of Gene Therapy, 29(8), 2441-2455. https://doi.org/10.1016/j.ymthe.2021.04.024
Dulla, Kalyan, et al. "Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations." Molecular therapy : the journal of the American Society of Gene Therapy vol. 29,8 (2021): 2441-2455. doi: https://doi.org/10.1016/j.ymthe.2021.04.024
Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, Turunen JJ, Chan HL, Schulkens IA, Vorthoren L, den Besten C, Buil L, Schmidt I, Miao J, Venselaar H, Zang J, Neuhauss SCF, Peters T, Broekman S, Pennings R, Kremer H, Platenburg G, Adamson P, de Vrieze E, van Wijk E. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021 Aug 04;29(8):2441-2455. doi: 10.1016/j.ymthe.2021.04.024. Epub 2021 Apr 23. PMID: 33895329; PMCID: PMC8353187.
Copy Download .nbib Format: NLM
Patients' Perceptions of Healthcare Quality at Hospitals Measured by the Revised Humane Caring Scale.

Journal of patient experience

Al-Jabri FYM, Turunen H, Kvist T.
PMID: 34926803
J Patient Exp. 2021 Dec 13;8:23743735211065265. doi: 10.1177/23743735211065265. eCollection 2021.

The patients' perceptions are central to quality improvement of the healthcare system worldwide. This study aimed to examine patients' perceptions of quality care and investigate the demographic factors related to the overall patients' perceptions. The Revised Humane Caring Scale...

Cite
Al-Jabri FYM, Turunen H, Kvist T. Patients' Perceptions of Healthcare Quality at Hospitals Measured by the Revised Humane Caring Scale. J Patient Exp. 2021;8:23743735211065265doi: 10.1177/23743735211065265.
Al-Jabri, F. Y. M., Turunen, H., & Kvist, T. (2021). Patients' Perceptions of Healthcare Quality at Hospitals Measured by the Revised Humane Caring Scale. Journal of patient experience, 823743735211065265. https://doi.org/10.1177/23743735211065265
Al-Jabri, Fatma Yaqoob Mohammed, et al. "Patients' Perceptions of Healthcare Quality at Hospitals Measured by the Revised Humane Caring Scale." Journal of patient experience vol. 8 (2021): 23743735211065265. doi: https://doi.org/10.1177/23743735211065265
Al-Jabri FYM, Turunen H, Kvist T. Patients' Perceptions of Healthcare Quality at Hospitals Measured by the Revised Humane Caring Scale. J Patient Exp. 2021 Dec 13;8:23743735211065265. doi: 10.1177/23743735211065265. eCollection 2021. PMID: 34926803; PMCID: PMC8674720.
Copy Download .nbib Format: NLM
iTReX: Interactive exploration of mono- and combination therapy dose response profiling data.

Pharmacological research

ElHarouni D, Berker Y, Peterziel H, Gopisetty A, Turunen L, Kreth S, Stainczyk SA, Oehme I, Pietiäinen V, Jäger N, Witt O, Schlesner M, Oppermann S.
PMID: 34848323
Pharmacol Res. 2021 Nov 27;175:105996. doi: 10.1016/j.phrs.2021.105996. Epub 2021 Nov 27.

High throughput screening methods, measuring the sensitivity and resistance of tumor cells to drug treatments have been rapidly evolving. Not only do these screens allow correlating response profiles to tumor genomic features for developing novel predictors of treatment response,...

Cite
ElHarouni D, Berker Y, Peterziel H, et al. iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacol Res. 2021;175:105996doi: 10.1016/j.phrs.2021.105996.
ElHarouni, D., Berker, Y., Peterziel, H., Gopisetty, A., Turunen, L., Kreth, S., Stainczyk, S. A., Oehme, I., Pietiäinen, V., Jäger, N., Witt, O., Schlesner, M., & Oppermann, S. (2021). iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacological research, 175105996. https://doi.org/10.1016/j.phrs.2021.105996
ElHarouni, Dina, et al. "iTReX: Interactive exploration of mono- and combination therapy dose response profiling data." Pharmacological research vol. 175 (2021): 105996. doi: https://doi.org/10.1016/j.phrs.2021.105996
ElHarouni D, Berker Y, Peterziel H, Gopisetty A, Turunen L, Kreth S, Stainczyk SA, Oehme I, Pietiäinen V, Jäger N, Witt O, Schlesner M, Oppermann S. iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacol Res. 2021 Nov 27;175:105996. doi: 10.1016/j.phrs.2021.105996. Epub 2021 Nov 27. PMID: 34848323.
Copy Download .nbib Format: NLM
Showing 289 to 291 of 291 entries